BIIB analyst estimates
Biogen (BIIB) analyst ratings, the average price target and its range, and every firm's latest call.
BIIB analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Robert W. Baird | Biogen price target raised to $290 from $250 at Baird | $290.00 |
| Oct 29, 2026 | UBS | Biogen price target raised to $300 from $270 at UBS | $300.00 |
| Oct 29, 2026 | Argus Research | Argus Upgrades Biogen (BIIB) to Buy | $280.00 |
| Oct 29, 2026 | Wedbush | Biogen price target raised to $225 from $212 at Wedbush | $225.00 |
| Oct 29, 2026 | RBC Capital | Biogen price target raised to $272 from $256 at RBC Capital | $272.00 |
| Oct 12, 2026 | BMO Capital | Biogen price target raised to $220 from $208 at BMO Capital | $220.00 |
| Oct 9, 2026 | UBS | Biogen price target raised to $270 from $240 at UBS | $270.00 |
| Oct 8, 2026 | RBC Capital | Biogen price target lowered to $256 from $260 at RBC Capital | $256.00 |
| Sep 10, 2026 | HSBC | Biogen price target raised to $175 from $165 at HSBC | $175.00 |
| Sep 10, 2026 | Stifel Nicolaus | Biogen (BIIB) Reiterated at Buy by Stifel After Investor Meeting | $242.00 |
| Sep 3, 2026 | Piper Sandler | Biogen price target raised to $245 from $225 at Piper Sandler | $245.00 |
| Aug 25, 2026 | RBC Capital | Biogen price target raised to $260 from $240 at RBC Capital | $260.00 |
| Aug 13, 2026 | Wolfe Research | Biogen upgraded to Outperform from Peer Perform at Wolfe Research | $300.00 |
| Jul 30, 2026 | H.C. Wainwright | Biogen price target raised to $251 from $237 at H.C. Wainwright | $251.00 |
| Jul 30, 2026 | Morgan Stanley | Biogen price target raised to $231 from $222 at Morgan Stanley | $231.00 |
- 26 firms rate BIIB: 18 buy, 7 hold, 1 sell.
- The average price target is $252.58 from 12 analysts, from $175.00 to $300.00.
Updated 2026-11-02 23:59 UTC